Skip to main content
Top
Published in: Abdominal Radiology 6/2022

01-06-2022 | Magnetic Resonance Imaging | Special Section: Male pelvis

Magnetic resonance imaging findings of pure prostatic ductal adenocarcinomas: a case series

Authors: Hiromi Edo, Yasuyo Urase, Yoshiko Ueno, Ayumu Kido, Tsutomu Tamada, Yudai Asano, Kentaro Ida, Hisataka Ito, Takashi Koyama, Kosuke Miyai, Hitoshi Tsuda, Hiroshi Shinmoto

Published in: Abdominal Radiology | Issue 6/2022

Login to get access

Abstract

Purpose

This study aimed to investigate the characteristics of magnetic resonance imaging (MRI) findings in pure prostatic ductal adenocarcinoma.

Methods

From January 2009 to February 2020, seven patients who were diagnosed with pure prostatic ductal adenocarcinoma and had a referable preoperative MRI scan were included in the study. We evaluated the following MRI findings for each tumor: size, location, presence of multi-cystic component, and apparent diffusion coefficient (ADC) value.

Results

The median maximum diameter of the tumors was 22 mm (range 19–70 mm). Regarding transverse distribution, five tumors were located in the periurethral area and two were located peripherally apart from the urethra. Two of the seven tumors had cystic components. The median ADC value of the tumors was 0.754 × 10–3 mm2/s (range 0.570–0.963 × 10–3 mm2/s). Based on the transverse distribution and components of the tumors on MRI, ductal adenocarcinomas were classified into three types: type I as a non-cystic tumor located peripherally apart from the urethra (29%, two cases); type II as a non-cystic tumor located in the periurethral area (43%, three cases); and type III as a tumor with a multi-cystic component (29%, two cases).

Conclusion

The non-cystic mass with periurethral distribution (type II) and multi-cystic mass (type III) may be characteristic features that differentiate pure ductal adenocarcinoma from ordinary acinar adenocarcinoma on MRI.
Literature
6.
go back to reference Ranasinha N, Omer A, Philippou Y, Harriss E, Davies L, Chow K, Chetta PM, Erickson A, Rajakumar T, Mills IG, Bryant RJ, Hamdy FC, Murphy DG, Loda M, Hovens CM, Corcoran NM, Verrill C, Lamb AD (2021) Ductal adenocarcinoma of the prostate: a systematic review and meta‐analysis of incidence, presentation, prognosis, and management. BJUI Compass 2:13–23. https://doi.org/10.1002/bco2.60CrossRefPubMedPubMedCentral Ranasinha N, Omer A, Philippou Y, Harriss E, Davies L, Chow K, Chetta PM, Erickson A, Rajakumar T, Mills IG, Bryant RJ, Hamdy FC, Murphy DG, Loda M, Hovens CM, Corcoran NM, Verrill C, Lamb AD (2021) Ductal adenocarcinoma of the prostate: a systematic review and meta‐analysis of incidence, presentation, prognosis, and management. BJUI Compass 2:13–23. https://​doi.​org/​10.​1002/​bco2.​60CrossRefPubMedPubMedCentral
12.
go back to reference Yamashita S, Inaba Y, Soma F, Katayama Y (2005) Pure prostatic papillary adenocarcinoma with ductal features. Hinyokika Kiyo 51:207–209PubMed Yamashita S, Inaba Y, Soma F, Katayama Y (2005) Pure prostatic papillary adenocarcinoma with ductal features. Hinyokika Kiyo 51:207–209PubMed
13.
go back to reference Henderson-Jackson E, Sexton W, Zhang J, Hakam A, Petrovskyy VS, Bui MM, Chuang ST (2012) Cystic prostatic ductal adenocarcinoma: an unusual presentation and cytological diagnosis. Ann Clin Lab Sci 42:81–88PubMed Henderson-Jackson E, Sexton W, Zhang J, Hakam A, Petrovskyy VS, Bui MM, Chuang ST (2012) Cystic prostatic ductal adenocarcinoma: an unusual presentation and cytological diagnosis. Ann Clin Lab Sci 42:81–88PubMed
21.
go back to reference Erdogdu I, Tuna B, Yorukoglu K, Montironi R (2022) Biomarkers in urinary tract and male genital system carcinomas, ductal adenocarcinoma. In: Sariogle S, Sagol O, Aysal A (eds) Biomarkers in Carcinoma of Unknown Primary, Springer Nature, Berlin pp 276. https://doi.org/10.1007/978-3-030-84432-5 Erdogdu I, Tuna B, Yorukoglu K, Montironi R (2022) Biomarkers in urinary tract and male genital system carcinomas, ductal adenocarcinoma. In: Sariogle S, Sagol O, Aysal A (eds) Biomarkers in Carcinoma of Unknown Primary, Springer Nature, Berlin pp 276. https://​doi.​org/​10.​1007/​978-3-030-84432-5
24.
go back to reference Shazer RL, Luthringer D, Agus DB, Gross ME (2004) Ductal adenocarcinoma of the prostate. Clin Adv Hematol Oncol 2:393–395; discussion 396. Shazer RL, Luthringer D, Agus DB, Gross ME (2004) Ductal adenocarcinoma of the prostate. Clin Adv Hematol Oncol 2:393–395; discussion 396.
30.
go back to reference Marcal LP, Surabhi VR, Ramani NS, Katabathina VS, Paspulati RM, Prasad SR (2022) Mesenchymal neoplasms of the prostate and seminal vesicles: Spectrum of disease with radiologic-pathologic correlation. Radiographics 210084. https://doi.org/10.1148/rg.210084 Marcal LP, Surabhi VR, Ramani NS, Katabathina VS, Paspulati RM, Prasad SR (2022) Mesenchymal neoplasms of the prostate and seminal vesicles: Spectrum of disease with radiologic-pathologic correlation. Radiographics 210084. https://​doi.​org/​10.​1148/​rg.​210084
Metadata
Title
Magnetic resonance imaging findings of pure prostatic ductal adenocarcinomas: a case series
Authors
Hiromi Edo
Yasuyo Urase
Yoshiko Ueno
Ayumu Kido
Tsutomu Tamada
Yudai Asano
Kentaro Ida
Hisataka Ito
Takashi Koyama
Kosuke Miyai
Hitoshi Tsuda
Hiroshi Shinmoto
Publication date
01-06-2022
Publisher
Springer US
Published in
Abdominal Radiology / Issue 6/2022
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-022-03454-z

Other articles of this Issue 6/2022

Abdominal Radiology 6/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine